Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) unit Chengdu StarRay Therapeutics obtained clinical trial approval for [18F]F-SR031 injection from China's National Medical Products Administration.
The drug will be tested for positron emission tomography imaging of fibroblast activation protein-positive lesions in patients with solid tumors, a Monday bourse filing showed.